Allergan to acquire medical aesthetics company for $195m
18-09-2018
Mylan partners to make Botox biosimilar
06-03-2018
Seattle Genetics to acquire biotech company for $614m
02-02-2018
miodrag ignjatovic / iStockphoto.com
Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Allergan, botox, mergers and acquisitions, Elastagen, clinical-stage, tissue repair, elastin, medical devices
